首页> 外文期刊>Biochemical Genetics >Epigenetic Modifications Linked to T2D, the Heritability Gap, and Potential Therapeutic Targets
【24h】

Epigenetic Modifications Linked to T2D, the Heritability Gap, and Potential Therapeutic Targets

机译:与T2D,遗传性间隙和潜在治疗目标相关的表观遗传修饰

获取原文
获取原文并翻译 | 示例
           

摘要

With the pandemic of type 2 diabetes (T2D), there is an ever-increasing need to fully understand the underlying mechanisms of the disease. Type 2 diabetes shows a high heritability risk (25-80%); however, genes account only for 10% of this risk. From all the risk factors for diabetes, epigenetic mechanisms have the highest statistical scoring in explaining the disease. A multitude of organ-specific epigenomic changes have been linked to type 2 diabetes. Nutritional influences, mainly in the early life, physical activity level, environmental toxins act as epigenetic factors and the recognized epigenetic changes can represent a therapeutical target, new drugs being currently in development for this application. Our current review focuses on the most common epigenetic modifications linked to type 2 diabetes or insulin resistance, the potentially emerging epigenetic-related interventions and pharmacoepigenetic knowledge.
机译:随着2型糖尿病(T2D)的大流行,需要完全了解疾病的潜在机制。 2型糖尿病显示出高遗传性风险(25-80%); 但是,基因仅占这种风险的10%。 从糖尿病的所有风险因素,表观遗传机制都具有最高的统计评分在解释疾病。 多种器官特异性表观蛋白变化与2型糖尿病有关。 营养影响,主要在早期生活,身体活动水平,环境毒素作为表观因素和认可的表观遗传变化可以代表治疗目标,目前正在开发这种申请的新药。 我们目前的审查重点介绍与2型糖尿病或胰岛素抵抗有关的最常见的表观遗传修饰,可能出现了相关的表观遗传学相关干预和药物观念知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号